Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Fortin, Patricia M ^a   Tejani, Aaron M ^b   Bassett, Ken ^a   Musini, Vijaya M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b FRASER HEALTH AUTHORITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PREDNISOLONE;

ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; HUMAN; INFECTION; MICROSCOPIC POLYANGIITIS; MORTALITY; POPULATION RESEARCH; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RISK FACTOR; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 70049094425     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007057.pub2     Document Type: Review

References (19)

1. * Jayne DRW, Chapel, H, Adu, D, Misbah, S, ODonoghue, D, Scott, D, Lockwood, CM. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Quarterly Journal of Medicine 2000;93:433-439.
2. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al.Prospective study of TNFalpha blockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Journal of the American Society of Nephrology 2004;15(3):717-721 (Pubitemid 38294802)
3. Chung SA, Seo P. Advances in the use of biologic agents for the treatment of systemic vasculitis. Current Opinion in Rheumatology 2009;21:3-9.
4. Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis, and response to treatment in polyarteritis.. Mayo Clinic Proceedings 1980;55(3):146-155 (Pubitemid 10116473)
5. de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.. Nephrology Dialysis Transplantation 2001;16(10):2018-2027
6. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al.Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & Rheumatism 2005;52(8):2461-2469 (Pubitemid 41117433)
7. Esper GJ, Johnson JS. Update on the treatment of Wegener's granulomatosis.. Bulletin on the Rheumatic Diseases. 1999;48(11):1-4.
8. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis.. Current Opinion in Rheumatology 2006;18(1):25-32.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414): 557-60
10. BMJ 2003;327(7414):557-560
11. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al.Wegener's granulomatosis: an analysis of 158 patients. Annals of Internal Medicine 1992;116(6):488-498
12. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al.A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. New England Journal of Medicine 2003;349(1):36-44. (Pubitemid 36765101)
13. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, emery P, et al.Birmingham Vasculitis Activity Score in Systemic Necrotizing Vasculitis. QJM 1994;87(11):671-678 (Pubitemid 24334817)
14. Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Annals of Internal Medicine 1995;123(12):925-932
15. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al.An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis & Rheumatism 2000;43(5):1021-1032 (Pubitemid 30368179)
16. Scott DG, Watts, RA. Systemic Vasculitis:epidemiology, classification, and environmental factors. Annals of the Rheumatic Diseases 2000;59(3):161-163
17. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. New England Journal of Medicine 1996;335(1):16-20.
18. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis.. New England Journal of Medicine 2005;352(4):351-361
19. Wung PK, Stone JH. Therapeutics of Wegener's granulomatosis. Nature Clinical Practice Rheumatology 2006;2(4):192-200.